|
Press Releases |
|
![](/images/company/Helsinn.jpg) |
|
Wednesday, May 9, 2018 |
|
Helsinn Group announces the launch of the IV formulation of AKYNZEO(R) (fosnetupitant/palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the intravenous formulation of AKYNZEO(R) (a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) for injection has been launched in the United States by its U.S. subsidiary, Helsinn Therapeutics (U.S.), Inc.. more info >> |
|
Friday, April 20, 2018 |
|
Helsinn Group announces the FDA approval of the IV formulation of AKYNZEO(R) (fosnetupitant/ palonosetron) in the United States |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces that the U.S. Food and Drug Administration (FDA) has approved the intravenous formulation of AKYNZEO(R) (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing CINV. more info >> |
|
Tuesday, April 17, 2018 |
|
Taiho Pharmaceutical and Helsinn Group present preclinical data at AACR Annual Meeting for a RET inhibitor under co-development as an attractive compound for anticancer therapy |
Taiho Pharmaceutical Co., Ltd., a Japanese R&D-driven specialty pharma focused on oncology and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announce that they are collaborating on the development of an investigational highly-selective RET inhibitor TAS0286/HM05, being evaluated in non-small cell lung cancer and other carcinomas. more info >> |
|
Wednesday, March 28, 2018 |
|
Helsinn Healthcare S.A.: Winners of the inaugural Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announced that Lorenzo Pradella of GreenBone Ortho, srl and Gitte Pedersen of Genomic Expression, Inc. have been chosen as winners of the first ever Lyfebulb-Helsinn Innovation Awards in Oncology. more info >> |
|
Friday, March 2, 2018 |
|
Helsinn Healthcare S.A.: Eleven finalists have been chosen for the first ever Lyfebulb-Helsinn Innovation Summit & Award in Oncology |
Lyfebulb, a patient empowerment platform that connects patients, industry and investors to support user-driven innovation in chronic diseases, and Helsinn, with activities focused on early-stage investments in areas of high unmet patient need, today announce the names of the eleven companies launched by patient entrepreneurs who are chosen as finalists for the Lyfebulb-Helsinn Innovation Summit & Award in Oncology. more info >> |
|
Tuesday, October 17, 2017 |
|
Helsinn Pharmaceuticals (Beijing) Co. Ltd. Opens Office in Shanghai, China |
Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, today announces the approval of Helsinn Pharmaceuticals (Beijing) Co. Ltd., Shanghai branch, on August 7, 2017 by the Shanghai Administration for Industry and Commerce with a 30-year term. The full address and contact details of the Shanghai branch are found at the end of this announcement. more info >> |
|
Friday, September 9, 2016 |
|
Helsinn and PatientsLikeMe Announce Results of NSCLC Patient Survey on Weight Loss |
Helsinn Therapeutics (U.S.) Inc., the pharmaceutical group focused on building quality cancer care, and patient network PatientsLikeMe have unveiled findings from an online survey that captured experiences and insights about unintended weight loss and its burden among 95 patients living with non-small cell lung cancer. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Fujitsu-sponsored professional golfer Ayaka Furue victorious in the Amundi Evian Championship
Jul 16, 2024 23:26 JST
|
|
|
Best BLUETTI Prime Day Deals on Portable Power Stations and Solar Generators
Jul 16, 2024 22:00 HKT/SGT
|
|
|
Lexaria Preparing For Strategic Growth
Jul 16, 2024 21:20 HKT/SGT
|
|
|
'Alamein Festival' Launches Exciting Second Edition for 2024
Jul 16, 2024 21:00 HKT/SGT
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 21:00: JST
|
|
|
China Medical System (867.HK) Reincluded in S&P Global Sustainability Yearbook (China Edition) and Maintained MSCI ESG "AA" Rating
Jul 16, 2024 20:00 HKT/SGT
|
|
|
How Artificial Intelligence Can Help Give Your Business a Boost
Jul 16, 2024 19:30 HKT/SGT
|
|
|
U.S. Polo Assn. Proudly Partners with the 2024 Outsourcing Inc. Royal Charity Polo Cup
Jul 16, 2024 19:00 HKT/SGT
|
|
|
Neste and Mitsubishi Corporation agree on strategic partnership to develop supply chains for renewable chemicals and plastics
Jul 16, 2024 18:36 JST
|
|
|
NEC technology reliably measures sea levels from a greater distance
Jul 16, 2024 17:45 JST
|
|
|
全球发展数字经济直播访谈会正式举办 外方来华参会高级别代表走进东方甄选直播间
Jul 16, 2024 15:08 HKT/SGT
|
|
|
巨星傳奇(6683.HK)解禁後首個交易日 收盤報10.4港元 升幅達2.97%
Jul 16, 2024 15:04 HKT/SGT
|
|
|
巨星传奇(6683.HK)解禁后首个交易日: 收盘报10.4港元 升幅达2.97%
Jul 16, 2024 14:58 HKT/SGT
|
|
|
全球發展數字經濟直播訪談會正式舉辦 外方來華參會高級別代表走進東方甄選直播間
Jul 16, 2024 14:25 HKT/SGT
|
|
|
Fujitsu and Cohere launch strategic partnership and joint development to provide generative AI for enterprises
Jul 16, 2024 15:13 JST
|
|
|
|
More News >> |
|
|
|
|
|